Media Release

• Seminar to focus on data from ASH meeting
• Webcast available on December 10

Copenhagen, Denmark; December 5, 2013 – Genmab A/S (OMX: GEN) will webcast its Post ASH investor seminar focused on the company’s latest developments in antibody innovation on December 10, 2013 from 7:30PM to 9:30PM CET.  At the seminar key opinion leaders will discuss and put into perspective data from studies of ofatumumab and daratumumab presented at the 2013 Annual Meeting of the American Society of Hematology (ASH) and Genmab will provide information on progress with the company’s proprietary antibody technologies, and expected performance milestones for 2014. 

The following cancer experts and senior Genmab staff will attend the event: 

• Professor Peter Hillmen, Professor of Experimental Haematology, University of Leeds and Honorary Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
• Dr. Paul Richardson, Clinical Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, Boston MA, USA
• Professor Torben Plesner, Department of Hematology, Vejle Hospital, Vejle, Denmark
• Dr. Jan van de Winkel, President and CEO, Genmab
• David Eatwell, Executive Vice President and CFO, Genmab
• Dr. Nikolai Constantin Brun, Vice President, Medical Department, Genmab

To view the webcast via WebEx, visit:
http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16533/28919/Lobby/default.htm.

WebEx viewers may submit questions during the Q&A portion of the live webcast via the webcast player or by dialing +44 203 426 2845 (international participants) or +1 877 841 4559 (US participants).  An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra^®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^TM; the DuoBody™ logo; HuMax^®; HuMax-CD20^®; DuoBody^®, HexaBody™ and UniBody^®. Arzerra^® is a registered trademark of GlaxoSmithKline.   

Media Release no. 07
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark